PTCT
PTC Therapeutics, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 18.67K | $1.18M | n/a | n/a |
| Q2 2026 | 115 | +8 | 59.02M | $4.80B | +13 | −5 |
| Q1 2026 | 110 | -8 | 65.31M | $4.45B | +9 | −18 |
| Q4 2025 | 117 | 0 | 67.93M | $5.16B | +1 | n/a |
| Q3 2025 | 22 | +2 | 38.04M | $2.33B | +2 | n/a |
| Q2 2025 | 17 | 0 | 34.63M | $1.69B | +1 | −1 |
| Q1 2025 | 14 | +2 | 16.93M | $862.87M | +2 | n/a |
| Q4 2024 | 12 | 0 | 14.84M | $670.12M | n/a | n/a |
| Q3 2024 | 11 | -2 | 14.00M | $519.42M | n/a | −2 |
| Q2 2024 | 13 | n/a | 14.28M | $436.54M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 11.77K | -5.2% | $736,206 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 2 | Assenagon Asset Management S.A. | 6.90K | -50.0% | $446,917 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 348 holders, 95.15M shares, $6.33B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 382 sh · $22,973
Director · 2.12K sh · $126,063
Officer · 192 sh · $12,338
Director · 2.45K sh · $155,091
Director · 53 sh · $3,389
Officer · 435 sh · $27,910
Officer · 1.64K sh · $104,881
Director · 376 sh · $25,737
Director · 9.62K sh · $652,796
Director · 7.01K sh · $471,854
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology